The IMPA1 Knockout HT29 Polyclonal Cells represent a polyclonal population of human colorectal adenocarcinoma cells in which the IMPA1 gene has been functionally disrupted using CRISPR/Cas9-mediated genome editing. This knockout model provides a powerful loss-of-function system to investigate the role of inositol monophosphatase 1 (IMPA1) in phosphoinositide metabolism and associated signaling networks. By ablating IMPA1 activity, these cells enable researchers to study lithium-sensitive pathways and inositol-dependent cellular processes without the confounding effects of residual enzyme function.
The HT29 cell line serves as an established and widely utilized model of human colorectal adenocarcinoma. Derived from a primary colon carcinoma, HT29 cells exhibit epithelial morphology and retain key characteristics of intestinal epithelial cells, making them particularly suitable for cancer biology and signal transduction research. Their well-characterized growth properties and genetic background provide a consistent platform for probing the molecular mechanisms underlying colon cancer, including proliferation, differentiation, and response to therapeutic agents.
IMPA1 encodes a magnesium-dependent inositol monophosphatase that catalyzes the dephosphorylation of inositol monophosphate to free inositol, an essential step in phosphoinositide recycling. The enzyme is regulated by substrate availability and is directly inhibited by lithium. IMPA1 functions as a homodimer and provides the inositol required for synthesis of phosphatidylinositol and its derivatives, including PI(4,5)P2. Upon cell stimulation, PIP2 hydrolysis releases IP3 and DAG, which respectively mobilize calcium and activate protein kinase C. Consequently, IMPA1 activity influences the PI3K/AKT pathway, as phosphoinositide substrates are necessary for AKT membrane recruitment and phosphorylation. In IMPA1 knockout cells, impaired inositol recycling leads to reduced inositol pools, blunted IP3-mediated calcium signaling, and decreased AKT phosphorylation, creating a condition that mimics lithium treatment.
In the context of HT29 colon carcinoma cells, IMPA1 knockout offers a unique window into the intersection of inositol metabolism and cancer-relevant signaling. Colorectal tumors often display aberrant activation of the PI3K/AKT pathway, and the availability of inositol can modulate the amplitude and duration of these signals. By eliminating IMPA1 activity, researchers can examine how phosphoinositide recycling contributes to cell proliferation, survival, and therapeutic responses in a colorectal cancer background. Moreover, the model permits investigation of lithium??s effects on cancer cells, potentially uncovering mechanisms of drug sensitivity or resistance dependent on inositol homeostasis.
This product is ideally suited for a broad range of biomedical investigations, including mechanistic studies of lithium action, bipolar disorder modeling, dissection of phosphoinositide signaling, and screening of small molecules targeting inositol-dependent pathways. The polyclonal knockout population can be employed in quantitative assays such as western blotting for IMPA1 and phospho-AKT, RT-qPCR, LC-MS-based inositol quantification, lithium sensitivity dose-response curves, and cell proliferation or apoptosis measurements. For additional information, please contact Ascent Research.
